Global Gene Therapies For Rare Diseases market is expected to reach US$ 11,441.6 Million by 2030, with a CAGR of 21.7% during a forecast period of 2022-2030.
Equities analysts forecast that Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) will post earnings per share of ($0.40) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Chemomab Therapeutics’ earnings. Chemomab Therapeutics posted earnings of ($0.22) per share in the same quarter last year, which indicates a negative […]
/PRNewswire/ A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled.
Zacks Investment Research lowered shares of Chemomab Therapeutics (NASDAQ:CMMB – Get Rating) from a hold rating to a strong sell rating in a research report released on Monday, Zacks.com reports. According to Zacks, “Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high […]
Chemomab Therapeutics (NASDAQ:CMMB) Raised to Buy at Zacks Investment Research etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.